



© Africa Studio / Adobe Stock

★ FEATURED

A VR platform brings eye testing into focus

PeriVision's AI-powered system aims to make sight-saving diagnostics faster, fairer, and more accessible

Share    

Follow Sectors Save  

Organisation

Organisation name

PeriVision

Location

 Switzerland

Funding amount

\$2M - \$5M

Funding stage

Seed

Organisation website

<https://www.perivision.com/>

[View organisation profile](#)

Springwise Take

Jialin Guo

Spotted: Across the world, millions risk losing their vision from diseases like glaucoma, often because diagnosis comes too late. The World Health Organization estimates that 2.2 billion people live with vision impairments, and half of these cases could be prevented or cured with timely detection. Yet current eye testing methods remain slow, costly, and tied to bulky equipment which creates long waiting lists and limited access to care, especially outside major hospitals.

Now, Swiss medtech startup PeriVision wants to change that. Spun out from the University of Bern and the University Hospital Bern, the company is rethinking how eye health is monitored. Its platform, VisionOne, uses a standard virtual reality (VR) headset combined with AI algorithms to deliver quick, precise, and patient-friendly visual field tests. This helps clinicians spot signs of glaucoma and other retinal diseases much earlier.

What sets PeriVision apart is its blend of portability, data intelligence, and inclusivity. By swapping out traditional testing machines for lightweight VR headsets, clinics can run tests anywhere from a small practice to a patient's home, without compromising accuracy. The AI system not only interprets test results but also tracks subtle changes over time, offering insights that can guide personalised treatment and prevent vision loss before it happens.

Behind the company is a team driven by a clear mission to make eye testing and care accessible to everyone, everywhere. Their approach has already earned strong recognition, from EIT Health's Wild Card award to Innosuisse's scale-up support.

Following a recent CHF 2.4 million (\$3 million) seed round led by ARYA VC, PeriVision is now expanding its platform with new retina disease tests, enhanced AI capabilities, and cloud-based integrations for seamless use in clinics and research settings. The next step is to expand its presence across US, UK and EU so that protecting sight becomes faster, simpler, and within reach for all.

Ask Scout AI...

- [What AI system enhances surgical efficiency and sustainability?](#)
- [What AI voice solutions assist healthcare providers?](#)
- [How does AI predict surgical complications recently?](#)
- [What recent digital health advancements improve health access?](#)
- [How are AI innovations improving robotics recently?](#)

Ask a question



Similar

Portable biosensor detects mental disorders

A low-cost saliva test offers a new path toward early detection and personalised treatment

A VR platform to overcome speech anxiety

This virtual reality training can help people reduce fears of public speaking in as little as 30 minutes

AI enhances lung cancer monitoring

A deep learning platform could transform the way doctors track tumour developments

Using sound to move artificial muscles

How could sound waves and bubbles help revolutionise biomedical devices?

[Discover more innovations](#)